The aim of this research program is to develop highly-specific small-molecule telomerase inhibitors through structure-guided design, wherein an atomic-level molecular structure provides a template for the custom-design of small molecules to block enzymatic activity in a predicted manner. Structure-guided design has led to the development of highly successful cancer therapeutics, such as Gleevec, targeting the bcr-Abl fusion, and Venetoclax, targeting Bcl2 and developed at the WEHI.
Started: 1 January 2018
Ending: 31 December 2019
